Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Scribe Therapeutics Q3 2026 Results: Net Loss of $9.86M

Scribe Therapeutics reported a net loss of $33.0 million for the nine months ended September 30, 2026, compared to a $12.6 million loss in the prior year period, primarily due to a significant decrease in collaboration revenue. During the quarter, the company completed its initial public offering and concurrent private placement, resulting in a cash and cash equivalents balance of $172.1 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.620.1
Profit before tax-9.61.8
Net income-9.91.5
EPS (diluted, $ a share)$-0.68$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-91.9%
Source

10-Q filed with the SEC, NASDAQ: SCTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Scribe Therapeutics, Inc.: key numbers

Share price
$15.37Close, Nov 16
Market cap
$291M
Shares outstanding
18.93MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Scribe Therapeutics, Inc.

All →
4:20 PM ET 8-K
Financial Results

Scribe Therapeutics Financial Results

Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.

“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”

Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.